- Home
- HMST vs CKPT Comparison
HMST vs CKPT Comparison
Compare HMST & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- CKPT
- Stock Information
- Founded
- HMST 1921
- CKPT 2014
- Country
- HMST United States
- CKPT United States
- Employees
- HMST N/A
- CKPT N/A
- Industry
- HMST Major Banks
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- CKPT Health Care
- Exchange
- HMST Nasdaq
- CKPT Nasdaq
- Market Cap
- HMST 169.7M
- CKPT 172.4M
- IPO Year
- HMST 2012
- CKPT 2017
- Fundamental
- Price
- HMST $12.01
- CKPT $4.04
- Analyst Decision
- HMST Hold
- CKPT Buy
- Analyst Count
- HMST 3
- CKPT 3
- Target Price
- HMST $14.50
- CKPT $4.33
- AVG Volume (30 Days)
- HMST 261.7K
- CKPT 5.7M
- Earning Date
- HMST 04-29-2025
- CKPT 03-28-2025
- Dividend Yield
- HMST N/A
- CKPT N/A
- EPS Growth
- HMST N/A
- CKPT N/A
- EPS
- HMST N/A
- CKPT N/A
- Revenue
- HMST $75,702,000.00
- CKPT $41,000.00
- Revenue This Year
- HMST $163.76
- CKPT $102,182.93
- Revenue Next Year
- HMST $7.69
- CKPT $351.71
- P/E Ratio
- HMST N/A
- CKPT N/A
- Revenue Growth
- HMST N/A
- CKPT N/A
- 52 Week Low
- HMST $8.09
- CKPT $1.38
- 52 Week High
- HMST $16.10
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- HMST 78.52
- CKPT 65.90
- Support Level
- HMST $9.02
- CKPT $4.01
- Resistance Level
- HMST $9.34
- CKPT $4.07
- Average True Range (ATR)
- HMST 0.50
- CKPT 0.03
- MACD
- HMST 0.34
- CKPT -0.00
- Stochastic Oscillator
- HMST 91.03
- CKPT 70.00
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.